Vaxart (NASDAQ:VXRT) Share Price Crosses Above 200-Day Moving Average of $0.83

Vaxart, Inc. (NASDAQ:VXRT) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.83 and traded as high as $0.86. Vaxart shares last traded at $0.80, with a volume of 741,585 shares changing hands.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $4.00 target price on shares of Vaxart in a research report on Thursday, September 7th.

Vaxart Trading Down 6.2 %

The company has a 50 day simple moving average of $0.71 and a 200 day simple moving average of $0.83. The stock has a market capitalization of $121.28 million, a PE ratio of -1.25 and a beta of 0.71.

Institutional Trading of Vaxart

Several institutional investors and hedge funds have recently added to or reduced their stakes in VXRT. JPMorgan Chase & Co. raised its stake in Vaxart by 22.9% during the 1st quarter. JPMorgan Chase & Co. now owns 58,203 shares of the biotechnology company’s stock valued at $293,000 after acquiring an additional 10,851 shares during the last quarter. MetLife Investment Management LLC raised its stake in Vaxart by 56.1% during the 1st quarter. MetLife Investment Management LLC now owns 68,707 shares of the biotechnology company’s stock valued at $346,000 after acquiring an additional 24,690 shares during the last quarter. Vanguard Group Inc. raised its stake in Vaxart by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 6,074,906 shares of the biotechnology company’s stock valued at $30,617,000 after acquiring an additional 90,272 shares during the last quarter. Mariner LLC raised its stake in shares of Vaxart by 66.7% during the 1st quarter. Mariner LLC now owns 250,755 shares of the biotechnology company’s stock worth $1,264,000 after buying an additional 100,343 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Vaxart by 2.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 905,313 shares of the biotechnology company’s stock worth $4,563,000 after buying an additional 18,900 shares in the last quarter. 19.04% of the stock is owned by hedge funds and other institutional investors.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase II clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine, an oral vaccine platform, which is in preclinical stage; coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection; human papillomavirus therapeutic vaccine that targets HPV 16 and HPV 18 for cervical cancers and precancerous cervical dysplasia.